Management of Pancytopenia

Medications to Avoid or Use with Caution

The American Academy of Dermatology recommends avoiding tetracycline antibiotics, such as minocycline and doxycycline, in patients with pancytopenia due to the risk of blood abnormalities, including agranulocytosis, hemolytic anemia, thrombocytopenia, and pancytopenia 3
The American Academy of Dermatology advises against using azathioprine in patients with pre-existing pancytopenia due to the significant risk of bone marrow suppression 4
The American Society of Clinical Oncology recommends using chemotherapeutic agents with caution in patients with pancytopenia, as they can worsen the condition, and potentially requiring dose modifications 5
The American Society of Clinical Oncology suggests discontinuing immune checkpoint inhibitors if severe cytopenia develops, as they can cause immune-related hematologic toxicities, including pancytopenia 6

The Infectious Diseases Society of America recommends avoiding rectal procedures, such as rectal thermometers, enemas, suppositories, and rectal examinations, in patients with pancytopenia due to the risk of bleeding and infection 7
The American Society of Hematology advises against invasive procedures, especially with severe thrombocytopenia, due to the risk of bleeding and other complications 2

The European Society for Medical Oncology recommends maintaining hemoglobin at least 8 g/dl (higher in patients with comorbidities) in patients requiring repeated RBC transfusions, and avoiding restrictive transfusion strategies 8
The European Society for Medical Oncology suggests avoiding prophylactic platelet transfusions, except in patients receiving myelosuppressive drugs 8

The Infectious Diseases Society of America recommends avoiding exposure to potential pathogens, such as plants and fresh flowers in hospital rooms, sick visitors or healthcare workers, and raw fruits and vegetables unless well-cleaned, in patients with neutropenia 7

The International Society on Thrombosis and Haemostasis recommends avoiding full-dose anticoagulation without platelet support in cancer patients with acute thrombosis and severe thrombocytopenia (<50 × 10^9/L) 1
The European Society for Medical Oncology suggests avoiding standard chemotherapy regimens without dose adjustments in patients with hematologic malignancies and pancytopenia 5

The European Society for Medical Oncology recommends not delaying treatment in progressive disease, such as hairy cell leukemia with progressive pancytopenia, and treatment should be initiated promptly 5